<abstract><sec><title>Background and Objectives</title><p>This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent.</p></sec><sec><title>Methods</title><p>This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES)™ and Promus Element™. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis &gt;50%, reference vessel diameter of 2.5–4.0 mm, and lesion length ≤40 mm. The primary endpoint was in-stent late lumen loss at 9-month quantitative coronary angiography follow-up. Secondary endpoints were in-segment late lumen loss, binary restenosis rate, death, myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis during 9 months of follow-up.</p></sec><sec><title>Results</title><p>We enrolled 38 patients for the Genoss DES™ group and 39 patients for the Promus Element™ group. In-stent late lumen loss at 9 months was not significantly different between the 2 groups (0.11±0.25 vs. 0.16±0.43 mm, p=0.567). There was no MI or stent thrombosis in either group. The rates of death (2.6% vs. 0%, p=0.494), TLR (2.6% vs. 2.6%, p=1.000), and TVR (7.9% vs. 2.6%, p=0.358) at 9 months were not significantly different.</p></sec><sec><title>Conclusion</title><p>This first-in-patient study of the Genoss DES™ stent showed excellent angiographic outcomes for in-stent late lumen loss and major adverse cardiac events over a 9-month follow-up.</p></sec></abstract><sec><title>RESULTS</title><p>Between March 2013 and April 2015, 85 patients were screened for enrollment in the study. Five patients did not meet inclusion criteria and a total of 80 patients were randomly assigned to the Genoss DES™ or Promus Element™ group at a 1:1 ratio. In the Genoss DES™ group, 2 patients were excluded as one patient did not receive stent implantation and the other patient had a protocol violation. In the Promus Element™ group, 1 patient was excluded owing to the patient's withdrawal from the study (<xref>Figure 1</xref>).</p><fig><label>Figure 1</label><caption><p>Flow chart of patient enrollment.</p><p>DES = drug-eluting stent.</p></caption><graphic></graphic></fig><p>Baseline clinical and angiographic characteristics are shown in <xref>Tables 1</xref> and <xref>2</xref>, respectively. There were no significant differences in clinical characteristics including age and clinical diagnosis between the 2 groups (<xref>Table 1</xref>). Target vessels were not significantly different, but the left anterior descending artery was targeted more often in the Promus Element™ group. Stent overlap was performed in 8 (21.1%) patients in the Genoss DES™ group and in 3 (7.7%) patients in the Promus Element™ group (<xref>Table 2</xref>).</p><table-wrap><label>Table 1</label><caption><title>Baseline clinical characteristics</title></caption><alternatives><graphic></graphic><table><col/><col/><col/><col/><col/><thead><tr><th></th><th>Genoss DES™ (n=38)</th><th>Promus Element™ (n=39)</th><th>p</th></tr></thead><tbody><tr><td>Age (years)</td><td>64±8</td><td>63±8</td><td>0.591</td></tr><tr><td>Male</td><td>31 (81.6)</td><td>31 (79.5)</td><td>1.000</td></tr><tr><td>Diabetes</td><td>12 (31.6)</td><td>12 (30.8)</td><td>1.000</td></tr><tr><td>Hypertension</td><td>24 (63.2)</td><td>29 (74.4)</td><td>0.332</td></tr><tr><td>Hyperlipidemia</td><td>15 (39.5)</td><td>13 (33.3)</td><td>0.640</td></tr><tr><td>Current smoker</td><td>9 (23.7)</td><td>13 (33.3)</td><td>0.451</td></tr><tr><td>Diagnosis</td><td></td><td></td><td>0.549</td></tr><tr><td></td><td>Stable angina</td><td>17 (44.7)</td><td>19 (48.7)</td></tr><tr><td></td><td>Unstable angina</td><td>21 (55.3)</td><td>19 (48.7)</td></tr><tr><td></td><td>Silent ischemia</td><td>0</td><td>1 (2.6)</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are shown as mean±standard deviation or number (%).</p><p>DES = drug-eluting stent.</p></table-wrap-foot></table-wrap><table-wrap><label>Table 2</label><caption><title>Angiographic and procedural characteristics</title></caption><alternatives><graphic></graphic><table><col/><col/><col/><col/><col/><thead><tr><th></th><th>Genoss DES™ (n=38)</th><th>Promus Element™ (n=39)</th><th>p</th></tr></thead><tbody><tr><td>Target vessel</td><td></td><td></td><td>0.068</td></tr><tr><td></td><td>Left anterior descending</td><td>18 (47.3)</td><td>26 (66.7)</td></tr><tr><td></td><td>Left circumflex</td><td>4 (10.5)</td><td>6 (15.4)</td></tr><tr><td></td><td>Right coronary</td><td>16 (42.1)</td><td>7 (17.9)</td></tr><tr><td>AHA/ACC classification</td><td></td><td></td><td>0.089</td></tr><tr><td></td><td>A</td><td>4 (10.5)</td><td>7 (17.9)</td></tr><tr><td></td><td>B1</td><td>6 (15.8)</td><td>14 (35.9)</td></tr><tr><td></td><td>B2</td><td>10 (26.3)</td><td>8 (20.5)</td></tr><tr><td></td><td>C</td><td>18 (47.4)</td><td>10 (25.6)</td></tr><tr><td>Stent diameter (mm)</td><td>3.14±0.26</td><td>3.15±0.30</td><td>0.970</td></tr><tr><td>Stent length (mm)</td><td>25.5±8.6</td><td>24.1±5.0</td><td>0.395</td></tr><tr><td>Mean stent number</td><td>1.2</td><td>1.1</td><td>0.099</td></tr><tr><td>Stent overlap</td><td>8 (21.1)</td><td>3 (7.7)</td><td>0.114</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are shown as mean±standard deviation or number (%).</p><p>ACC = American College of Cardiology; AHA = American Heart Association; DES = drug-eluting stent.</p></table-wrap-foot></table-wrap><p>Angiographic follow-up at 9 months was performed for all patients, and IVUS follow-up was performed in 35 (92%) patients in the Genoss DES™ group and in 37 (95%) patients in the Promus Element™ group. QCA results are shown in <xref>Table 3</xref>. There were no significant differences in RVD. For the primary endpoint, in-stent late lumen loss at 9 months was not significantly different between the groups (0.11±0.25 mm for Genoss DES™ vs. 0.16±0.43 mm for Promus Element™, p=0.567) nor was in-segment late lumen loss (0.11±0.26 mm for Genoss DES™ vs. 0.15±0.43 mm for Promus Element™, p=0.558). Angiographic restenosis at 9 months was observed in 1 (2.6%) patient in the Genoss DES™ group and in 2 (5.1%) patients in the Promus Element™ group (p=1.000). IVUS minimal lumen area after stenting during the index procedure (6.95±1.98 vs. 7.47±2.47 mm<sup>2</sup>, p=0.272) and after 9 months (6.95±1.98 vs. 7.29±2.34 mm<sup>2</sup>, p=0.508) were not significantly different (<xref>Table 4</xref>). For clinical outcomes, there were no MI or stent thrombosis events during 9-month follow-up. One death occurred in the Genoss DES™ group due to aggravated renal function 6 months after the index procedure. However, the rate of death, MI, TLR, and TVR at 9 months were not significantly different (<xref>Table 5</xref>).</p><table-wrap><label>Table 3</label><caption><title>QCA analysis</title></caption><alternatives><graphic></graphic><table><col/><col/><col/><col/><col/><col/><thead><tr><th></th><th>Genoss DES™ (n=38)</th><th>Promus Element™ (n=39)</th><th>p</th></tr></thead><tbody><tr><td>RVD (mm)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Pre-procedure</td><td>3.24±0.41</td><td>3.12±0.43</td><td>0.199</td></tr><tr><td></td><td></td><td>Post-procedure</td><td>3.30±0.30</td><td>3.33±0.30</td><td>0.652</td></tr><tr><td></td><td></td><td>9-month follow-up</td><td>3.17±0.35</td><td>3.16±0.39</td><td>0.932</td></tr><tr><td>Minimal lumen diameter (mm)</td><td></td><td></td><td></td></tr><tr><td></td><td>In-stent</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Pre-procedure</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td></td><td></td><td>Post-procedure</td><td>2.95±0.35</td><td>3.03±0.30</td><td>0.269</td></tr><tr><td></td><td></td><td>9-month follow-up</td><td>2.84±0.42</td><td>2.87±0.56</td><td>0.743</td></tr><tr><td></td><td>In-segment</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Pre-procedure</td><td>0.83±0.29</td><td>0.88±0.45</td><td>0.572</td></tr><tr><td></td><td></td><td>Post-procedure</td><td>2.90±0.27</td><td>3.00±0.36</td><td>0.159</td></tr><tr><td></td><td></td><td>9-month follow-up</td><td>2.79±0.40</td><td>2.85±0.56</td><td>0.615</td></tr><tr><td>DS %</td><td></td><td></td><td></td></tr><tr><td></td><td>In-stent</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Pre-procedure</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td></td><td></td><td>Post-procedure</td><td>10.6±3.48</td><td>9.16±4.85</td><td>0.140</td></tr><tr><td></td><td></td><td>9-month follow-up</td><td>14.18±9.31</td><td>13.73±14.30</td><td>0.871</td></tr><tr><td></td><td>In-segment</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Pre-procedure</td><td>74.41±8.62</td><td>72.65±12.14</td><td>0.465</td></tr><tr><td></td><td></td><td>Post-procedure</td><td>12.10±3.93</td><td>10.12±4.94</td><td>0.056</td></tr><tr><td></td><td></td><td>9-month follow-up</td><td>15.46±9.39</td><td>14.54±14.08</td><td>0.738</td></tr><tr><td>Acute gain (mm)</td><td></td><td></td><td></td></tr><tr><td></td><td>In-stent</td><td>1.79±0.40</td><td>1.82±0.36</td><td>0.742</td></tr><tr><td></td><td>In-segment</td><td>1.74±0.39</td><td>1.78±0.38</td><td>0.579</td></tr><tr><td>Late loss (mm)</td><td></td><td></td><td></td></tr><tr><td></td><td>In-stent</td><td>0.11±0.25</td><td>0.16±0.43</td><td>0.567</td></tr><tr><td></td><td>In-segment</td><td>0.11±0.26</td><td>0.15±0.43</td><td>0.558</td></tr><tr><td>Lesion length (mm)</td><td>23.8±8.1</td><td>22.8±4.9</td><td>0.531</td></tr><tr><td>Restenosis</td><td>1 (2.6)</td><td>2 (5.1)</td><td>1.000</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are shown as mean±standard deviation or number (%).</p><p>DES = drug-eluting stent; DS = diameter stenosis; NA = not available; QCA = quantitative coronary angiography; RVD = reference vessel diameter.</p></table-wrap-foot></table-wrap><table-wrap><label>Table 4</label><caption><title>IVUS analysis results</title></caption><alternatives><graphic></graphic><table><col/><col/><col/><col/><col/><thead><tr><th></th><th>Genoss DES™ (n=35)</th><th>Promus Element™ (n=37)</th><th>p</th></tr></thead><tbody><tr><td>Minimal lumen area (mm<sup>2</sup>)</td><td></td><td></td><td></td></tr><tr><td></td><td>Post-procedure</td><td>6.71±1.74</td><td>7.28±2.41</td><td>0.255</td></tr><tr><td></td><td>9-month follow-up</td><td>6.30±1.78</td><td>6.72±2.28</td><td>0.387</td></tr><tr><td>Minimal stent area (mm<sup>2</sup>)</td><td></td><td></td><td></td></tr><tr><td></td><td>Post-procedure</td><td>6.90±1.77</td><td>7.47±2.47</td><td>0.272</td></tr><tr><td></td><td>9-month follow-up</td><td>6.95±1.98</td><td>7.29±2.34</td><td>0.508</td></tr><tr><td>EEM</td><td></td><td></td><td></td></tr><tr><td></td><td>Post-procedure</td><td>14.87±3.23</td><td>14.91±4.40</td><td>0.963</td></tr><tr><td></td><td>9-month follow-up</td><td>15.42±3.27</td><td>14.74±3.90</td><td>0.423</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are shown as mean±standard deviation.</p><p>DES = drug-eluting stent; EEM = external elastic membrane; IVUS = intravascular ultrasound.</p></table-wrap-foot></table-wrap><table-wrap><label>Table 5</label><caption><title>Clinical outcomes</title></caption><alternatives><graphic></graphic><table><col/><col/><col/><col/><col/><thead><tr><th></th><th>Genoss DES™ (n=38)</th><th>Promus Element™ (n=39)</th><th>p</th></tr></thead><tbody><tr><td>Death</td><td>1 (2.6)</td><td>0</td><td>0.494</td></tr><tr><td></td><td>Cardiac</td><td>0</td><td>0</td><td>1.000</td></tr><tr><td></td><td>Non-cardiac</td><td>1 (2.6)</td><td>0</td><td>0.494</td></tr><tr><td>MI</td><td>0</td><td>0</td><td>1.000</td></tr><tr><td>TLR</td><td>1 (2.6)</td><td>1 (2.6)</td><td>1.000</td></tr><tr><td>TVR</td><td>3 (7.9)</td><td>1 (2.6)</td><td>0.358</td></tr><tr><td>Stent thrombosis</td><td>0</td><td>0</td><td>1.000</td></tr></tbody></table></alternatives><table-wrap-foot><p>Data are shown as number (%).</p><p>DES = drug-eluting stent; MI = myocardial infarction; TLR = target lesion revascularization; TVR = target vessel revascularization.</p></table-wrap-foot></table-wrap></sec>